Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

[Transdermal estrogenic therapy in menopause].

T Nencioni, F Polvani, M Penotti

    Minerva Endocrinologica
    |January 1, 1989
    PubMed
    Summary
    This summary is machine-generated.

    Related Concept Videos

    You might also read

    Related Articles

    Articles linked to this work by shared authors, journal, and citation graph.

    Sort by
    Same author

    Risk factors for type 2 diabetes in women attending menopause clinics in Italy: a cross-sectional study.

    Climacteric : the journal of the International Menopause Society·2006
    Same author

    Factors associated with climacteric symptoms in women around menopause attending menopause clinics in Italy.

    Maturitas·2005
    Same author

    Effects of androgen supplementation of hormone replacement therapy on the vascular reactivity of cerebral arteries.

    Fertility and sterility·2001
    Same author

    Blood flow in the internal carotid and middle cerebral arteries: effects of continuous oral conjugated equine estrogens administration with monthly progestogen supplementation on postmenopausal women.

    Menopause (New York, N.Y.)·1999
    Same author

    The effect of tamoxifen and transdermal 17beta-estradiol on cerebral arterial vessels: a randomized controlled study.

    American journal of obstetrics and gynecology·1998
    Same author

    Alteration in the pulsatility index values of the internal carotid and middle cerebral arteries after suspension of postmenopausal hormone replacement therapy: a randomized crossover study.

    American journal of obstetrics and gynecology·1996
    Same journal

    Polycystic ovary syndrome, amenorrhea and the diagnostic role of anti-Müllerian hormone.

    Minerva endocrinologica·2021
    Same journal

    Effects of Mediterranean diet on semen parameters in healthy young adults: a randomized controlled trial.

    Minerva endocrinologica·2021
    Same journal

    Next generation of strain specific probiotics in diabetes treatment: the case of Prevotella copri.

    Minerva endocrinologica·2020
    Same journal

    New perspectives in neuroendocrine neoplasms research from tumor xenografts in zebrafish embryos.

    Minerva endocrinologica·2020
    Same journal

    Codon bias analyses on thyroid carcinoma genes.

    Minerva endocrinologica·2020
    Same journal

    The possible role of endocrine dysfunction of adipose tissue in gestational diabetes mellitus.

    Minerva endocrinologica·2020
    See all related articles

    Percutaneous estrogen therapy offers faster relief for menopausal hot flashes compared to oral treatments. Both methods show similar metabolic effects, providing effective options for managing climacteric syndrome.

    Area of Science:

    • Endocrinology
    • Menopause research
    • Pharmacology

    Background:

    • Percutaneous estrogen preparations bypass hepatic metabolism, offering new treatment avenues for the climacteric syndrome.
    • Hormone therapy is a common treatment for menopausal symptoms, with various administration routes available.

    Purpose of the Study:

    • To compare the efficacy and tolerability of percutaneous 17-beta-estradiol-oral progestin versus oral conjugated estrogens-progestin.
    • To evaluate the control of menopausal symptoms and biohumoral changes between the two treatment groups.

    Main Methods:

    • A comparative study involving 42 postmenopausal women with severe symptoms.
    • Patients were divided into two groups: one receiving percutaneous therapy, the other receiving oral therapy.

    Related Experiment Videos

    Main Results:

    • Percutaneous administration demonstrated a more rapid control of vasomotor symptoms.
    • Both percutaneous and oral administration showed similar metabolic effects.
    • Tolerability data was also assessed for both treatment regimens.

    Conclusions:

    • Percutaneous estrogen therapy provides a faster onset of action for vasomotor symptom relief in the climacteric syndrome.
    • The study suggests percutaneous administration is a viable and effective alternative to oral hormone therapy.
    • Further research could explore long-term outcomes and patient-reported satisfaction for both methods.